| Company* (Country; Symbol) | Company | Type/Product Area | Terms/Details (Date) |
| Cleveland BioLabs Inc. (CBLI) | Bioprocess Capital Ventures (Russia) | Agreement for a joint venture to develop the Curaxin compounds for cancer applications | CBLI would transfer rights to its pipeline of Curaxin anticancer molecules to the new joint venture, and BioProcess would contribute about $15M over three payments to support development (5/21) |
|
Notes: * Private companies are indicated with an asterisk. Unless otherwise noted, the trading symbols listed for public companies are on the Nasdaq market. | |||
